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Long-term outcomes after high-dose chemoradiotherapy for non-surgical
management of distal rectal cancer. First Author: Edina Dizdarevic, Vejle
Hospital, Vejle, Denmark
Background: Surgery is standard treatment for rectal cancer, but neoadjuvant
chemoradiotherapy (CRT) may result in clinical complete response (cCR) in
selected patients, allowing for non-surgical management (NSM). Prospective
studies of NSM strategies are sparse however, and long-term data on quality of
life (QoL) are limited. We conducted a single-arm phase II trial of high-dose
CRT for NSM of distal rectal cancer; we report secondary long-term patient-
reported outcomes (PROs), local regrowth and overall survival (OS) in patients
managed non-surgically. Methods: Fifty-one patients with resectable, T2 or
T3, N0–N1, low adenocarcinoma received 65Gy (IMRT, brachytherapy boost)
and oral tegafur-uracil. Patients with cCR 6 weeks after treatment (clinical
examination, MRI, biopsy) were referred for observation, and followed closely
with clinical examinations, endoscopies, PET-CTs, and PROs for 5 years.
Overall colorectal cancer specific QoL and specific symptom scores were
compared between timepoints using pairedWilcoxon tests. Local regrowthwas
estimated using cumulative incidence; overall survival using Kaplan-Meier
estimates. Results: Forty patients achieved cCR after treatment; 28 were in
follow-up at 24m, 21 at 36m, 18 at 60m. Patients left the trial due to local
tumor regrowth (n=12), distant metastases (n=3), new primary cancers (n=6)
and loss to follow-up (n=1). Average QoL score did not differ between baseline
(median 11.1) and 24m (13.7), 48m (11.1,) or 60m (6.9). See Table for
individual scores; only rectal bleeding deteriorated from baseline (significantly
worse at 24m). At median follow-up of 5.0 years, local regrowth rate and OS
were 31% (95 CI 15%-47%) and 85% (95 CI 75%-97%), respectively.
Conclusions: Long term follow-up after NSM of early rectal cancer showed
excellent general colorectal cancer QoL and local symptom scores.
(NCT00952926). EORTC QLQ – CR 29. Proportion reporting ‘quite a bit’ or
‘very much’ on symptom scales. Clinical trial information: NCT00952926.
Baseline (n=40) 24m (n=28) 48m (n=22) 60m (n=18)
Daytime urinary frequency 27% 12% 18% 11%
Urinary incontinence 0% 0% 9% 0%
Rectal pain 0% 4% 4% 0%
Blood in stools 8% 27% 23% 11%
Faecal incontinence 3% 7% 0% 0%
Daytime bowel movement frequency 14% 17% 17% 12%
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Simultaneous versus staged resection for synchronous colorectal cancer liver
metastases: A population-based cohort study. First Author: Pablo Emilio
Serrano Aybar, McMaster University, Hamilton, ON, Canada
Background: Simultaneous resection of colorectal cancer primary and liver
metastases is not performed routinely due to concerns about safety. We hy-
pothesized that simultaneous resection has steadily increased overtime and
that the outcomes are similar. Methods: Population-based cohort study of
patients undergoing resection for synchronous (resection of the primary co-
lorectal cancer and liver metastases within six months) liver metastases from
2006-2015 by linking administrative datasets in Ontario, Canada. Outcomes:
post-operative complications, length of hospital stay, and overall survival.
Survival for the staged group was measured from the last surgical resection to
death and estimated using Kaplan Meier and compared with the log-rank test.
Cox proportional hazard models were used to calculate risks for death. We
aimed to identify practice patterns, outcomes of simultaneous vs. staged
resections for these patients. Results: Of 2,738 patients undergoing colorectal
and liver resection for colorectal cancer, 1,168 were synchronous, of which,
442 underwent simultaneous resection. Rate of synchronous disease pre-
sentation increased on average by 3% per year (p = 0.02). Median length of
stay was shorter (8 vs. 11 days, p, 0.001); rate of major liver resections were
lower (17% vs. 65%, p , 0.001), and 90-day post-operative mortality was
higher (6% vs. 1%) for simultaneous resections. Major postoperative com-
plications were higher in the simultaneous group (28% vs. 23%, p = 0.067),
mostly due to a higher reoperation rate (6% vs. 3%, p = 0.034).Median overall
survival was worse with simultaneous resection (40 months, 95%CI 35-46 vs.
78months, 95%CI59-86). Risks factors forworse survivalwere comorbidities,
rurality, right-sided primary and simultaneous resection. There is selection bias
that favours survival in the staged group, as patients must have survived the
first operation and have stable disease in order to undergo the second oper-
ation. Conclusions: Simultaneous resection is associated with worse post-
operative outcomes. Considering selection bias, randomized studies would be
necessary to determine the role of simultaneous.
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Pathway analysis of hypoxia-related factors in early colorectal cancer patients
with poor prognosis. First Author: Yingxin Tan, The Sixth Affiliated Hospital
of Sun Yat-sen University, Guangzhou, China
Background: Colorectal cancer is one of the most common malignancies
with a high mortality rate. Patients with stage I and stage II colorectal cancer
have limited options for treatment. Hypoxia affects the activation and
regulation of colorectal cancer cells and participates in its invasion and
migration. However, there is lack of an accurate and non-invasive method for
assessing tumor hypoxia. The aim of this study was developing and
validating a hypoxia gene signature for predicting the outcome in stage I/II
colorectal cancer patients. At the same time , we hypothesized that analysis
of database of CITmicroarray dataset could identify important biomarkers for
stage I/II colorectal cancer patients. Methods: A total of 309 colorectal
cancer patients of early stage with complete clinical information were en-
rolled for construction generation of hypoxia-related gene signature (HRGS)
based on the CIT microarray dataset. 1877 colorectal cancer patients with
complete prognostic information in 5 independent datasets were divided
into a training cohort and two validation cohort (TCGA and meta-validation).
Prognostic analysis was assessed in these cohort to evaluate the predictive
value of HRGS. Results: Amodel of prognostic HRGS containing 14 hypoxia-
related genes was developed. In training cohort and two validation cohorts,
patients in hypoxia high-risk group satisfied by our HRGS had significant
poor disease free survival compared with those in the in the low risk group
(HR=4.35, 95% CI=2.30-8.23, P,0.001 in training cohort, HR=2.14,
95% CI=1.09-4.21, P=0.024 in TCGA cohort, HR=1.91, 95% CI=1.08-
3.39, P=0.024 in meta-validation cohort). When compared with Oncotype
DX, HRGS achieved an improved survival correlation in the training cohort
(mean C-index, 0.80 vs 0.65, P,0.05) and the validation cohort (mean C-
index, 0.70 vs 0.61 in the TCGA cohort, mean C-index, 0.68 vs 0.73 in the
meta-validation cohort). Analysis of the data found that patients with low
survival rates have significant relationships with genes regulated by the cell
cycle pathway, such as mTROC1, E2F, G2-M, mitotic, oxidative phos-
phorylation, MYC, PI3K-AKT-mTOR (P,0.005). Conclusions: HRGS was a
satisfactory prognostic prediction model for early stage colorectal patients.
Hypoxia-related genes that regulate the cell cycle pathway were associated
with prognosis in patients with stage I and stage II colorectal cancer. Further
researches are needed to assess the clinical effectiveness of the system and
the treatment options for biological targets.
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Clinical features and survival among patients with standard-onset versus
early-onset colorectal cancer by age groups.First Author: AnaAcunaVillaorduna,
Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY
Background: Colorectal cancer (CRC) incidence is increasing in patients
younger than 50 years old. Currently, there are discordant recommendations
regarding CRC screening: while the American Cancer Society favors to start
at age 45, the National Comprehensive Cancer Network and the US Pre-
ventive Task Force suggest starting at age 50. This study is aimed to compare
the incidence, clinical characteristics and survival of patients diagnosed
with standard-onset CRC (SO) versus early-onset colorectal cancer by age-
groups. Methods: Patients diagnosed with CRC at ages older than 35 were
identified using the SEER registry and categorized into four groups based on
age at diagnosis. EO1 (35-39), EO2 (40-44), EO3 (45-49) and SO (.50)
years, respectively. Incidence, clinical features and survival were compared
among groups. Results: 178 678 patients were identified. 9.2% were di-
agnosed before 50 years. Of these, 1.4%, 2.8% and 5.1% were EO1, EO2
and EO3; respectively. Patients with early-onset CRC (EO) had higher fre-
quency of Hispanics (13.9% vs. 8.4%, p,0.01), stage IV (24.8% vs.
17.3%, p,0.01), left-sided tumors (74.1% vs. 56.9%, p,0.01) and better
survival compared to SO. Among EO groups, the frequency of poor/anaplastic
grade was inversely proportional to age; stage IV was similar between EO2
and EO3 and lower in EO1. Black race, grade and stage were predictors of
mortality for all EO groups; laterality was a mortality predictor in EO2 and
EO3. Conclusions: EO-CRC and SO-CRC have different pathological features
that should be considered for CRC screening. Higher rates of stage IV disease
are encountered in patients between 40-49 years old; hence early screening
should be considered. Given higher rates of left-sided tumors, sigmoidos-
copy might be an adequate tool for most patients with EO-CRC.
EO1 EO2 EO3 SO p*
Incidence (per 100 000) 8.8 16.5 30.1 146.8
Male (%) 50.2\ 51.4 53.9 51.8 ,0.01
NHW (%) 1.1 2.3 4.5 92.1 ,0.01
NHB (%) 1.6 3.7 6.4 88.3 ,0.01
Hispanic (%) 2.7 4.3 7.4 85.5 ,0.01
Poorly/Anaplastic grade (%) 23.5 20 19 18.7 ,0.01
Sigmoid to anal (%) 65.2 66 67.1 49.9 0.14
Left-sided (%) 74.1 73.4 74.4 56.9 0.32
Stage IV (%) 17.3 26.6 24.7 24.3 ,0.01
5-year OS 64.5 66.6 65.9 54.9
p* comparison between EO groups
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